MPH Health Care AG Maintains Positive Outlook Amidst Portfolio Restructuring

First Berlin Equity Research GmbH recently updated its analysis of MPH Health Care AG, reaffirming a "BUY" recommendation with a target price of €37. This follows MPH's complete portfolio overhaul, characterized by a significant CRE Energy position write-down. Despite this, MPH's Net Asset Value only dropped by 12%, thanks to M1 Kliniken's strong performance, which generated nearly €34 million in free cash flow last year.

For 2025, MPH proposes a significant dividend increase to €5.00 per share, contingent on shareholder approval. If approved on July 9, this would result in a 19% yield, a development likely to be positively received given the company's past four-year dividend suspension.

Furthermore, M1's successful operational quarter and the profitable divestiture of Haemato bolster an optimistic future for the beauty sector. Analysts maintain a positive outlook on MPH's growth prospects.